Institute for Systems Biology to Work With Complete Genomics to Conduct Large-Scale Huntington`s Disease Study

Mon Nov 2, 2009 8:00am EST

* Reuters is not responsible for the content in this press release.

Project to Sequence an Unprecedented 100 Human Genomes in Just Six Months
SEATTLE & MOUNTAIN VIEW, Calif.--(Business Wire)--
The Institute for Systems Biology (ISB) and Complete Genomics Inc. announced
today that they are embarking on a large-scale human genome sequencing study of
Huntington`s disease (HD). ISB has engaged Complete Genomics to sequence 100
genomes, the majority of which will be used to investigate this disease, with
samples from affected individuals, family members, and matched controls to study
modifiers of disease presentation and progression. 

This will be the largest complete human genome disease association study
conducted to date, and will be the first 100-genome study produced by Complete
Genomics` newly expanded sequencing facility. The comparison of healthy and
diseased complete human genome sequences will enable genomewide association
studies with a focus on rare single nucleotide polymorphisms (SNPs), and
insertions and deletions that are incompletely accessible with current
genomewide SNP chip technologies. These will include rare variants in protein
coding regions of the genome (the "exome") as well as in regulatory regions. 

"It is when we start to look at genomics research on this scale that our
sequencing technology really comes into its own and we have the potential to
make truly revolutionary discoveries," said Dr. Clifford Reid, chairman,
president and CEO of Complete Genomics. "I am delighted that we have the
opportunity to partner with ISB in this effort to discover the genetic variants
responsible for modulating the presentation and progress of Huntington`s

ISB President Dr. Leroy Hood said, "We were pleased with the quality of the raw
sequencing data and variations reports that Complete Genomics generated for our
four-genome pilot project earlier this year. Its sequencing technology has the
requisite accuracy, consistency and low price point to enable us to begin
conducting this large-scale genomic study in this important patient population."

Huntington's disease is a devastating, hereditary, degenerative brain disorder
for which there is, at present, no effective treatment or cure, according to the
Huntington`s Disease Society of America. The Society adds that HD affects one
out of every 10,000 Americans, slowly diminishing the affected individual`s
ability to walk, think, talk and reason. 

For this study, ISB will supply the purified DNA samples and Complete Genomics
will sequence and identify variations for each genome. ISB will then do the
genetic analysis at the sequence level. 

About the Institute for Systems Biology

The Institute for Systems Biology (ISB) is an internationally renowned,
non-profit research institute headquartered in Seattle and dedicated to the
study and application of systems biology. Founded in 2000, ISB was established
to unravel the mysteries of complex biological systems and to identify
strategies for predicting and preventing human diseases such as cancer, diabetes
and AIDS. ISB's systems approach integrates biology, computation and
technological development, enabling scientists to analyze all elements in a
biological system rather than one gene or protein at a time. The Institute has
grown to 14 faculty members and more than 250 staff members; has an annual
budget of more than $35 million; and an extensive network of academic and
industrial partners. For more information about ISB, visit 

About Complete Genomics

Founded in 2006, Complete Genomics is a California company that has developed a
novel approach to sequencing human DNA that is revolutionizing the human genome
sequencing industry. Complete Genomics combines its proprietary third-generation
DNA sequencing technology with its high-performance computing capabilities to
deliver low-cost, high-quality genomic data on an unprecedented scale. The
company is currently building the world`s largest human genome sequencing
center. This development will allow academic and biopharmaceutical researchers,
for the first time, to conduct large-scale complete human genome studies that
will help identify the genetic underpinnings of complex diseases and drug
responses. For additional information about the company, please visit

Complete Genomics Inc.
Jennifer Turcotte, 650-943-2846
Vice President of Marketing
Institute for Systems Biology
Todd Langton, 206-732-1333
Associate Director of Communications and Public Relations
Waggener Edstrom Worldwide Healthcare
Lisa Osborne, 202-261-7806
Account Director

Copyright Business Wire 2009